Five Firms Advise on the Capital Increase for DBV Technologies

Overview


Emmanuelle Trombe, Bertrand Delafaye, Noëmie Fort and Pierre Menegaux led McDermott’s work for the French biopharmaceutical company DBV Technologies, which announced that it completed its new public offering of American Depositary Shares valued at $281.5 million.